Jacobio Pharmaceuticals Group Co., Ltd.

Research Jacobio Pharmaceuticals Group Co., Ltd. (1167.HK) on Bullrun: market cap HKD 4.09B, P/E 7.0. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Ticker1167.HK
ExchangeHK
CountryChina
SectorHealthcare
IndustryBiotechnology
CurrencyHKD
Market capHKD 4.09B
P/E7.0
Financial periodFY2025
RevenueCNY 53.53M
Revenue growth-65.6%
Net income-CNY 145.98M
Free cash flow-CNY 212.71M
Gross margin98.9%

Valuation Snapshot

latest market cap is HKD 4.09B; P/E is 7.0.

Peer valuation comparison

Latest P/E is 6.97x versus a Healthcare sector median of 21.75x (68.0% below).

Latest P/E is 6.97x versus a China median of 16.26x (57.2% below).

Five-year financial history

Year	Revenue	Net income	Free cash flow	Gross margin	Diluted EPS	Cash	Total debt	Equity
FY2025	CNY 53.53M	-CNY 145.98M	-CNY 212.71M	98.9%	-0.19	CNY 943.65M	CNY 165.17M	CNY 770.63M
FY2024	CNY 155.71M	-CNY 155.71M	-CNY 86.21M	100.0%	-0.2	CNY 1.17B	CNY 152.08M	CNY 923.18M
FY2023	CNY 63.52M	-CNY 359.12M	-CNY 402.86M	5.0%	-0.46	CNY 1.14B	CNY 209.91M	CNY 1.07B
FY2022	CNY 95.75M	-CNY 371.86M	-CNY 308.92M	13.2%	-0.49	CNY 1.28B	CNY 147.79M	CNY 1.28B

Valuation history

Year	Snapshot date	Market cap	P/E	Dividend yield	Annual dividend/share
2026	2026-10-18	HKD 4.09B	7.0	n/a	0

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0 HKD.

About Jacobio Pharmaceuticals Group Co., Ltd.

Jacobio Pharmaceuticals Group Co., Ltd., an investment holding company, engages in the in-house discovery and development of oncology therapies in the People's Republic of China. The company develops sitneprotafib (JAB-3312), an oral allosteric SHP2 inhibitor that is in a Phase III trial for non-small cell lung cancer (NSCLC); glecirasib (JAB-21822), a KRAS G12C allosteric inhibitor in Phase II trials for NSCLC, multi-tumor basket, and colorectal cancer;

Related stock research

China stocks China Healthcare stocks A-Z stock index

Other Healthcare stocks

Hualan Biological Engineering INC (002007.SZ) Shanghai RAAS Blood Products Co Ltd (002252.SZ) Asymchem Laboratories (Tianjin) Co., Ltd. (002821.SZ) CANbridge Pharmaceuticals Inc. (1228.HK) 3D Medicines Inc. (1244.HK) Ocumension Therapeutics (1477.HK) 3SBio Inc. (1530.HK) LongBio Pharma (Suzhou) Co., Ltd. (1779.HK) Innovent Biologics, Inc. (1801.HK) Viva Biotech Holdings (1873.HK) BioDlink International Company Limited (1875.HK) Shanghai Junshi Biosciences Co., Ltd. (1877.HK)

Frequently asked questions

What is Jacobio Pharmaceuticals Group Co., Ltd.'s market cap?

Jacobio Pharmaceuticals Group Co., Ltd.'s market capitalization is HKD 4.09B.

What is Jacobio Pharmaceuticals Group Co., Ltd.'s P/E ratio?

Jacobio Pharmaceuticals Group Co., Ltd.'s price-to-earnings (P/E) ratio is 7.0.

What does Jacobio Pharmaceuticals Group Co., Ltd. do?

Jacobio Pharmaceuticals Group Co., Ltd., an investment holding company, engages in the in-house discovery and development of oncology therapies in the People's Republic of China.